Vertex Pharmaceuticals Inc (VRTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vertex Pharmaceuticals Inc (VRTX) has a cash flow conversion efficiency ratio of 0.072x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.24 Billion) by net assets ($17.32 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vertex Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1991–2025)
This chart illustrates how Vertex Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Vertex Pharmaceuticals Inc debt and liabilities for a breakdown of total debt and financial obligations.
Vertex Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vertex Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Air Liquide SA
PA:AI
|
0.130x |
|
Crowdstrike Holdings Inc
NASDAQ:CRWD
|
0.111x |
|
GlaxoSmithKline plc
MX:GSKN
|
0.141x |
|
DBS GROUP ADR/4 SD 1
F:DEV
|
N/A |
|
State Bank of India
NSE:SBIN
|
-0.265x |
|
Lockheed Martin Corporation
NYSE:LMT
|
0.603x |
|
Bank of Montreal
TO:BMO
|
-0.016x |
|
Sanofi
F:SNW2
|
0.051x |
Annual Cash Flow Conversion Efficiency for Vertex Pharmaceuticals Inc (1991–2025)
The table below shows the annual cash flow conversion efficiency of Vertex Pharmaceuticals Inc from 1991 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Vertex Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.67 Billion | $3.63 Billion | 0.195x | +748.08% |
| 2024-12-31 | $16.41 Billion | $-492.60 Million | -0.030x | -114.92% |
| 2023-12-31 | $17.58 Billion | $3.54 Billion | 0.201x | -32.22% |
| 2022-12-31 | $13.91 Billion | $4.13 Billion | 0.297x | +13.41% |
| 2021-12-31 | $10.10 Billion | $2.64 Billion | 0.262x | -30.12% |
| 2020-12-31 | $8.69 Billion | $3.25 Billion | 0.375x | +45.23% |
| 2019-12-31 | $6.09 Billion | $1.57 Billion | 0.258x | -9.96% |
| 2018-12-31 | $4.44 Billion | $1.27 Billion | 0.286x | -30.77% |
| 2017-12-31 | $2.04 Billion | $844.94 Million | 0.414x | +134.49% |
| 2016-12-31 | $1.34 Billion | $236.10 Million | 0.176x | +152.76% |
| 2015-12-31 | $1.09 Billion | $-365.43 Million | -0.334x | +28.46% |
| 2014-12-31 | $1.10 Billion | $-513.20 Million | -0.467x | -1129.56% |
| 2013-12-31 | $1.36 Billion | $-51.57 Million | -0.038x | -117.52% |
| 2012-12-31 | $1.23 Billion | $267.84 Million | 0.217x | +45.75% |
| 2011-12-31 | $965.51 Million | $143.74 Million | 0.149x | +111.81% |
| 2010-12-31 | $503.97 Million | $-635.44 Million | -1.261x | -223.29% |
| 2009-12-31 | $1.10 Billion | $-427.59 Million | -0.390x | +58.87% |
| 2008-12-31 | $238.87 Million | $-226.48 Million | -0.948x | -1.88% |
| 2007-12-31 | $271.30 Million | $-252.48 Million | -0.931x | -1994.95% |
| 2006-12-31 | $505.94 Million | $-22.48 Million | -0.044x | +93.82% |
| 2005-12-31 | $239.18 Million | $-172.05 Million | -0.719x | +82.07% |
| 2004-12-31 | $35.44 Million | $-142.16 Million | -4.011x | -361.47% |
| 2003-12-31 | $192.84 Million | $-167.62 Million | -0.869x | -313.72% |
| 2002-12-31 | $378.58 Million | $-79.54 Million | -0.210x | -1136.94% |
| 2001-12-31 | $475.35 Million | $-8.07 Million | -0.017x | +64.72% |
| 2000-12-31 | $345.76 Million | $-16.64 Million | -0.048x | +68.33% |
| 1999-12-31 | $209.19 Million | $-31.80 Million | -0.152x | -20.34% |
| 1998-12-31 | $246.20 Million | $-31.10 Million | -0.126x | -270.90% |
| 1997-12-31 | $276.00 Million | $-9.40 Million | -0.034x | +88.95% |
| 1996-12-31 | $130.80 Million | $-40.30 Million | -0.308x | -64.26% |
| 1995-12-31 | $85.30 Million | $-16.00 Million | -0.188x | -34.62% |
| 1994-12-31 | $105.50 Million | $-14.70 Million | -0.139x | -180.20% |
| 1993-12-31 | $49.50 Million | $8.60 Million | 0.174x | +243.91% |
| 1992-12-31 | $43.90 Million | $-5.30 Million | -0.121x | -152.08% |
| 1991-12-31 | $52.20 Million | $-2.50 Million | -0.048x | -- |
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age a… Read more